Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omnitrope Lawsuit Could Further Delay FDA “Follow-On” Biologics Guidance

Executive Summary

Sandoz' lawsuit against FDA over the human growth hormone product Omnitrope could further complicate the agency's efforts to define a potential approval route for "follow-on" biologics

You may also be interested in...



Novartis’ Biogeneric Pipeline Has Six Projects; Pricing Issues Are A Focus

Novartis expects to file its second biosimilar application in the coming year, Sandoz CEO Andreas Rummelt stated during the Swiss drug maker's first quarter sales and earnings call April 24

Novartis’ Biogeneric Pipeline Has Six Projects; Pricing Issues Are A Focus

Novartis expects to file its second biosimilar application in the coming year, Sandoz CEO Andreas Rummelt stated during the Swiss drug maker's first quarter sales and earnings call April 24

User Fee Program Renewal Gets Trickier After Ruling In Omnitrope Court Case

Renewal of FDA's Prescription Drug User Fee Act could be complicated by a federal court ruling that the agency must take action on Sandoz' application for a follow-on version of Pfizer's recombinant human growth hormone Genotropin

Related Content

Topics

UsernamePublicRestriction

Register

PS046334

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel